Supernus Pharm (NQ: SUPN )
34.53
+0.10
(+0.29%)
Streaming Delayed Price
Updated: 11:46 AM EDT, Aug 21, 2024
Add to My Watchlist
Press Releases about Supernus Pharm
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
Supernus Announces Second Quarter 2024 Financial Results
August 06, 2024
Via GlobeNewswire
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
August 01, 2024
Via GlobeNewswire
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
![](https://mms.businesswire.com/media/20240502660298/en/478343/5/GPM_Logo_Colo.jpg)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
![](https://mms.businesswire.com/media/20240429598316/en/765953/22/Close_Up_Logo_HD_Blue.jpg)
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
Supernus Provides Regulatory Update for SPN-830
April 08, 2024
Via GlobeNewswire
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
Supernus to Participate in Two Upcoming Investor Conferences
March 06, 2024
Via GlobeNewswire
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
Via GlobeNewswire
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
Via GlobeNewswire
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
Supernus Announces Third Quarter 2023 Financial Results
November 08, 2023
Via GlobeNewswire
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
Supernus to Participate in the Jefferies London Healthcare Conference
November 07, 2023
Via GlobeNewswire
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
October 09, 2023
Via GlobeNewswire
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms
September 09, 2023
Via GlobeNewswire
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
Supernus to Participate in the Wells Fargo Healthcare Conference
August 31, 2023
Via GlobeNewswire
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
Bethany L. Sensenig Joins Supernus’ Board of Directors
August 21, 2023
Via GlobeNewswire
![](https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg)
Supernus Announces Second Quarter 2023 Financial Results
August 08, 2023
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.